Difelikefalin acetate

Difelikefalin (1 mg/kg; i.v.; continuous infusion; 2 hours) acetate produces a transient diuretic effect without altering blood pressure or pulse rate in normal anesthetized rats^[1].
Difelikefalin (0.3-1.0 mg/kg; i.v.; single injection; 1 hour pre-LPS) acetate improves tubular flow rate, and the 1.0 mg/kg dose preserves urine volume, in LPS-induced septic acute kidney injury in mice^[1].
Difelikefalin (0.3-1.0 mg/kg; i.v.; single injection; 1 hour pre-CLP) acetate improves tubular flow rate in CLP-induced polymicrobial sepsis-associated acute kidney injury in mice^[1].
Difelikefalin (0.3 mg/kg; i.v.; single injections; days 1-5 post-ischemia/reperfusion) acetate increases survival rate to over 80% in subsequent LPS-induced septic acute kidney injury in mice^[1].
Difelikefalin (1.0 mg/kg; i.v.; single injection; 1 hour pre-LPS) acetate improves tubular flow rate in LPS-induced septic acute kidney injury in mice, independent of renal innervation^[1].
Difelikefalin acetate significantly increases plasma IL-10 levels in LPS-induced septic acute kidney injury in mice^[1].
Difelikefalin (0.5 mg/kg; i.p.; twice daily; 14 days) acetate suppresses atopic dermatitis-associated itch in mice^[3].
Difelikefalin (1.0 mg/kg; i.p.; single dose) acetate rapidly reduces atopic dermatitis-associated scratching behavior in mice^[3].